Stay updated on Rilzabrutinib for CSU: H1 Resistant - Clinical Trial
Sign up to get notified when there's something new on the Rilzabrutinib for CSU: H1 Resistant - Clinical Trial page.

Latest updates to the Rilzabrutinib for CSU: H1 Resistant - Clinical Trial page
- Check5 days agoChange DetectedThe site footer now identifies the website as revision v3.8.1 instead of v3.8.0.SummaryDifference0.0%

- Check12 days agoChange DetectedThe study record for the rilzabrutinib Phase 2 trial is displayed instead of an error page, with detailed trial information and links to results-related publications and study documents.SummaryDifference100%

- Check19 days agoChange DetectedThe footer revision identifier changes from v3.7.2 to v3.8.0. The study record continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check33 days agoChange DetectedA notice about NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” appears above the page, and the site revision changes from v3.7.1 to v3.7.2. The study record itself remains unavailable behind a 403 error.SummaryDifference1%

- Check47 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1. The page continues to show a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check61 days agoChange DetectedA 403 Forbidden error page appears when attempting to view the study record, showing a 403 message. A Home button is present, indicating restricted access rather than the study content.SummaryDifference17%

Stay in the know with updates to Rilzabrutinib for CSU: H1 Resistant - Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rilzabrutinib for CSU: H1 Resistant - Clinical Trial page.